Sorry, you need to enable JavaScript to visit this website.
Rotate Device

Vivinex™ IOL

References
  1. Clinical Evaluation of the HOYA Vivinex™ IOL, HOYA data on file DoF-PHIV-101-SP2-12mIR-31082018 (2018). 
  2. HOYA data on file. DoF-CTM-21-002, HOYA Medical Singapore Pte. Ltd, 2021.
  3. Christiansen G, et al. Glistenings in the AcrySof intraocular lens: pilot study. J Cataract Refract Surg. 2001;27(5):728-733. 
  4. Tandogan, T. et al. In-vitro glistening formation in six different foldable hydrophobic intraocular lenses. In BMC Ophthalmol. 2021; 21, 126.
  5. Pérez-Merino P, Marcos S. Effect of intraocular lens decentration on image quality tested in a custom model eye. J Cataract Refract Surg. 2018;44(7):889-896. 
  6. Leydolt C, et al. Posterior Capsule Opacification With Two Hydrophobic Acrylic Intraocular Lenses: 3-Year Results of a Randomized Trial. Am J Ophthalmol. 2020;217:224-231. 
  7. De Giacinto C, et al. Surface properties of commercially available hydrophobic acrylic intraocular lenses: Comparative study. J Cataract Refract Surg. 2019;45(9):1330-1334.
  8. Werner L, et al. Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. J Cataract Refract Surg. 2019;45(10):1490-1497.
  9. Matsushima H,et al. Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. J Cataract Refract Surg. 2006;32(6):1035-1040.
  10. Farukhi MA, et al. Evaluation of uveal and capsule biocompatibility of a single-piece hydrophobic acrylic intraocular lens with ultraviolet-ozone treatment on the posterior surface. J Cataract Refract Surg. 2015;41(5):1081-1087.
  11. Nanavaty, M. et al. Edge profile of commercially available square-edged intraocular lenses: Part 2. In: Journal of cataract and refractive surgery 45 (6), 2019;p. 847–853.
  12. Eldred, J. et al. An In Vitro Human Lens Capsular Bag Model Adopting a Graded Culture Regime to Assess Putative Impact of IOLs on PCO Formation. In: Investigative ophthalmology & visual science 60 (1), 2019;p. 113–122.

Our Vivinex™ IOLs

Hoya Surgical Optics Vivinex IOL

Proven benefits for you and your patients:

Glistening-free hydrophobic IOL material for enhanced clarity1,2,3,4

Proprietary aspheric design to improve image quality5

Active oxygen processing treatment, a smooth surface, and square optic edge to reduce PCO2,6,7,8,9,10,11,12

References

*Third-party trademarks used herein are the property of their respective owners.

  1. Miyata A, et al. Clinical and experimental observation of glistening in acrylic intraocular lenses. Jpn J Ophthalmol. 2001;45(6):564-569. 
  2. Tandogan, T. et al. In-vitro glistening formation in six different foldable hydrophobic intraocular lenses. In BMC Ophthalmol. 2021; 21, 126.
  3. HOYA data on file. DoF-CTM-21-002, HOYA Medical Singapore Pte. Ltd, 2021.

Glistening-free clarity

Hoya Surgical Optics Vivinex IOL

In vitro glistening formation at 14x magnification2

Vivinex™ is rated glistening-free with 97.0% of lenses demonstrating <10 glistenings per 10mm x 2mm field and showing significantly less glistenings than AcrySof IQ SN60WF* (p<0.0001).3

References
  1. Pérez-Merino P, Marcos S. Effect of intraocular lens decentration on image quality tested in a custom model eye. J Cataract Refract Surg. 2018;44(7):889-896.

More than meets the eye

Watch how Vivinex™ improves image quality and reduces coma compared with other traditional negative aspheric IOLs.1

Play
References
  1. De Giacinto C, et al. Surface properties of commercially available hydrophobic acrylic intraocular lenses: Comparative study. J Cataract Refract Surg. 2019;45(9):1330-1334.
  2. Werner L, et al. Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. J Cataract Refract Surg. 2019;45(10):1490-1497.
  3. HOYA data on file. DoF-CTM-21-002, HOYA Medical Singapore Pte. Ltd, 2021.
  4. Leydolt C, et al. Posterior Capsule Opacification With Two Hydrophobic Acrylic Intraocular Lenses: 3-Year Results of a Randomized Trial. Am J Ophthalmol. 2020;217:224-231. 
  5. Eldred JA, et al. An In Vitro Human Lens Capsular Bag Model Adopting a Graded Culture Regime to Assess Putative Impact of IOLs on PCO Formation. Invest Ophthalmol Vis Sci. 2019;60(1):113-122.
  6. Nanavaty MA, et al. Edge profile of commercially available square-edged intraocular lenses: Part 2. J Cataract Refract Surg. 2019;45(6):847-853.

What features of an IOL limit PCO?

Hoya Surgical Optics Vivinex IOL

Vivinex™ is made from a novel hydrophobic acrylic, using a proprietary manufacturing process that includes a unique, active oxygen posterior surface treatment

Combined with its square edge design and smooth, regular IOL surface, it has been demonstrated to provide a low incidence of PCO in several studies.1-6

References
  1. Matsushima, H. et al. (2006): Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. In: Journal of cataract and refractive surgery 32 (6), p. 1035–1040.

Want to learn more?

Watch how our active oxygen posterior surface treatment helps to reduce PCO.1

Play
References

*Third-party trademarks used herein are the property of their respective owners.

  1. HOYA data on file. DoF-CTM-21-002, HOYA Medical Singapore Pte. Ltd, 2021.
  2. Leydolt C, et al. Posterior Capsule Opacification With Two Hydrophobic Acrylic Intraocular Lenses: 3-Year Results of a Randomized Trial. Am J Ophthalmol. 2020;217:224-231. 
  3. De Giacinto C, et al. Surface properties of commercially available hydrophobic acrylic intraocular lenses: Comparative study. J Cataract Refract Surg. 2019;45(9):1330-1334.
  4. Werner L, et al. Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. J Cataract Refract Surg. 2019;45(10):1490-1497.
  5. Matsushima H,et al. Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. J Cataract Refract Surg. 2006;32(6):1035-1040.
  6. Farukhi MA, et al. Evaluation of uveal and capsule biocompatibility of a single-piece hydrophobic acrylic intraocular lens with ultraviolet-ozone treatment on the posterior surface. J Cataract Refract Surg. 2015;41(5):1081-1087.
  7. Eldred JA, et al. An In Vitro Human Lens Capsular Bag Model Adopting a Graded Culture Regime to Assess Putative Impact of IOLs on PCO Formation. Invest Ophthalmol Vis Sci. 2019;60(1):113-122.
  8. Nanavaty MA, et al . Edge profile of commercially available square-edged intraocular lenses: Part 2. J Cataract Refract Surg. 2019;45(6):847-853.

Are you interested in clinical proof?

  Vivinex™ XY1 (HOYA)   AcrySof® IQ SN60WF (Alcon)
Objective
(EPCO score)
0.12 ± 0.19 n = 57 p < .026 0.24 ± 0.46 n = 57
Subjective
(slit lamp score)
0.30 ± 0.55 n = 67 p = .044 0.48 ± 0.84 n = 67
Nd:YAG rate 0.0% n = 67 p = 1.00 1.5 % n = 67
Objective
(AQUA score)
0.9 ± 0.8 n = 64 P < .001 1.4 ± 1.1 n = 62
Subjective
(slit lamp score)
1.4 ± 1.4 n = 64 P = .001 2.3 ± 2.0 n = 62
Nd:YAG rate 11.4% n = 70 p =  .23 18.6 %  n = 70

In a randomized multi-center trial, Vivinex™ demonstrated significantly lower objective and subjective PCO scores compared with AcrySof® IQ after 3 years.1

In a randomized single-center trial, Vivinex™ demonstrated significantly lower objective and subjective PCO scores compared with AcrySof® IQ after 3 years.2

These results confirm low occurrence of PCO in both IOL groups and significantly lower PCO incidence with Vivinex™ compared to AcrySof® IQ.

clinical proof of the effectiveness of Vivinex™ XY1, an intraocular lens (IOL) made from a hydrophobic acrylic material with a unique manufacturing process and active oxygen posterior surface treatment.

These results confirm low occurrence of PCO in both IOL groups and significantly lower PCO incidence with Vivinex™ compared to AcrySof® IQ*.

Vivinex™ is made from a novel hydrophobic acrylic, using a proprietary manufacturing process that includes a unique, active oxygen posterior surface treatment. Combined with its square edge design and smooth, regular IOL surface, it has been demonstrated to provide a low incidence of PCO in several studies.1-8

Scroll

scroll scroll